Reflection paper on the EU Pharmaceutical Strategy

  29 January 2021

The BEAM Alliance welcomes the European Commission’s Pharmaceutical Strategy, which recognises the development of novel antimicrobials as a prime example of an unmet medical need and proposes important measures to address the rising threat of antimicrobial resistance (AMR),
which requires urgent action. We count on the Commission to foster short-term solutions in parallel to long-term incentive reforms, and to consider the specific challenges faced by European small and medium-sized enterprises (SMEs) in the field. Europe’s preparedness for the next global health crisis may be tested sooner than its legislative pace can keep up with.

Further reading: BEAM Alliance
Author(s): Beam Alliance
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!